Reduction of glucose is the hallmark of diabetes therapy proven to reduce microand macro-
vascular risk in patients with type 1 diabetes. However glucoselowering efficacy trials in type …

Patients with type 2 diabetes are at high risk for development of cardiovascular disease,
including myocardial infarction, stroke, heart failure, and cardiovascular death. Multiple large …

We stand on the threshold of an exciting area when at long last we have novel antidiabetic
therapies proven to reduce cardiovascular events. Recent large-scale trials have finally …

Cardiovascular (CV) disease is the most alarming complication of diabetes mellitus (DM),
and a strategy aiming at cardiovascular event prevention in diabetes mellitus has long been …

Diabetes is a leading cause of cardiovascular disease and its associated morbidity. While
the medical community has had access to numerous glucose lowering therapies over the …

There is a growing body of evidence that diabetes represents a significant and largely
modifiable risk factor for cardiovascular disease (CVD). It is known to markedly increase the …

Cardiovascular disease (CVD) is the main reason for premature death in patients with type 2
diabetes. Hyperglycemia, the hallmark of diabetes, has long been considered the link …

Despite the risk of atherosclerosis has progressively declined over the past few decades,
subjects with type 2 diabetes mellitus (T2DM) continue to experience substantial excess of …

Landmark trials on diabetes control have shown variable results in terms of cardiovascular
benefits, with the majority showing a favorable effect of glycemic control on microvascular …

Cardiovascular disease remains a leading cause of morbidity and mortality in people with
types 1 or 2 diabetes mellitus. Although beneficial roles for strict control of hyperglycemia …